RAREUltragenyx Pharmaceutical Inc.

1. Oct 7, 2026On October 6, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) to the buyer.Material agreement entered · Form 8-K
2. Sep 17, 2026On September 17, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, for the treatment of pediatric patients with mucopolysaccharidosis …Other event · Form 8-K
3. Sep 2, 2026On September 2, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome.Other event · Form 8-K
4. Aug 19, 2026On August 19, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced the U.S. Food and Drug Administration (the “FDA”) granted accelerated approval for GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and pediatric patients eight years and older with glycogen storage …Other event · Form 8-K
5. Aug 11, 2026On August 7, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) and Baylor Research Institute (“BRI”) entered into a settlement agreement with Esjay Pharma Private Limited and Esjay Pharma LLC (collectively, “Esjay”) resolving patent litigation related to the Company’s DOJOLVI® (triheptanoin) oral liquid.Other event · Form 8-K
6. Aug 4, 2026Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update.Earnings release · press release
7. May 18, 2026As reported below, at its Annual Meeting of Stockholders (the “Annual Meeting”) on May 14, 2026, the stockholders of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) approved the Third Amended and Restated 2023 Incentive Plan (the “Third A&R 2023 Plan”)Director or officer change · Form 8-K
8. May 5, 2026Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update.Earnings release · press release
9. Apr 2, 2026On April 2, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has accepted for review the Company’s resubmitted Biologics License Application seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy …Other event · Form 8-K
10. Mar 30, 2026On March 30, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has cleared the Investigational New Drug (“IND”) application for UX016, an investigational small molecule prodrug of sialic acid (“SA”) being evaluated as a …Other event · Form 8-K
11. Mar 12, 2026On March 12, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing positive results from its Phase 3 Enh3ance study of DTX301, an investigational AAV8 gene therapy for the treatment of ornithine transcarbamylase (“OTC”) deficiency.Other event · Form 8-K
12. Feb 23, 2026On February 23, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has accepted for review the Biologics License Application (the “BLA”) seeking approval of DTX401 AAV gene therapy (pariglasgene brecaparvovec) for the treatment …Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.